Chitotriosidase Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Chitotriosidase (CHIT1) is a chitinase enzyme produced by activated microglia and macrophages that serves as a biomarker for neuroinflammation and microglial activation in neurodegenerative diseases. It is the most active chitinase in humans and is particularly elevated in conditions involving chronic inflammation.[1]
Chitotriosidase represents a unique class of biomarkers that directly reflect microglial activation state, providing insight into the neuroinflammatory component of neurodegenerative diseases. Unlike markers that assess neuronal injury (such as neurofilament light chain), chitotriosidase measures the immune response component, offering complementary diagnostic and prognostic information.[2]
| Property |
Value |
| Gene |
CHIT1 |
| Protein |
Chitotriosidase |
| UniProt |
Q9NRR2 |
| Molecular Weight |
~50 kDa (secreted) |
| Cellular Localization |
Secreted, extracellular |
| Enzyme Family |
Glycosyl hydrolase family 18 |
| Chromosome |
1q31-q32 |
The CHIT1 gene spans approximately 13 kb and consists of:
- 12 exons encoding the protein
- Promoter region with response elements for inflammatory cytokines
- Common polymorphism: 24-bp duplication in exon 10 (approximately 35% of population are homozygous deficient)
Chitotriosidase (466 amino acids) has a distinctive domain organization:
- Signal peptide (1-22 aa): N-terminal secretion signal directing co-translational translocation to the endoplasmic reticulum
- Catalytic domain (23-333 aa): Glycosyl hydrolase family 18 domain with conserved DXDXE motif
- Chitin-binding domain (350-466 aa): C-terminal domain enabling substrate binding
The active site contains the catalytic residue Glu204, which facilitates hydrolysis of chitin substrates through a retaining mechanism.
Chitotriosidase hydrolyzes chitin, a polymer of N-acetylglucosamine:
- Physiological substrate: Despite enzymatic activity, chitin is not expressed in humans, suggesting vestigial function
- Synthetic substrates: Used in laboratory assays (4-Methylumbelliferyl chitotrioside)
- Activity measurement: Fluorometric detection of released 4-methylumbellifone
Chitotriosidase is not expressed in healthy individuals at significant levels, but is rapidly induced under inflammatory conditions:
- Macrophage Activation: Produced by activated tissue macrophages and monocyte-derived macrophages
- Innate Immunity: Represents a response to pathogen exposure, particularly parasitic infections
- Tissue Remodeling: Involved in wound healing and tissue repair processes
Chitotriosidase expression is tightly regulated by inflammatory mediators:
- Induced by: IL-6, IL-1β, TNF-α, IFN-γ
- Suppressed by: IL-4, IL-10, glucocorticoids
- Amplification: Autocrine and paracrine signaling enhances expression
Chitotriosidase serves as a specific marker of microglial activation in the central nervous system:
- Microglial phenotype: Associated with the M2 (alternatively activated) phenotype in early disease stages
- Temporal pattern: Elevated in early neuroinflammation, may decrease in later stages
- Regional specificity: Higher expression in regions with active pathology
The elevation of chitotriosidase in neurodegenerative diseases reflects:
- Chronic microglial activation: Ongoing immune response to protein aggregates
- Disease activity: Levels correlate with rate of disease progression
- Therapeutic target engagement: May reflect response to anti-inflammatory treatments
Chitotriosidase is elevated in Alzheimer's disease and provides unique information:[3]
| Finding |
Significance |
| CSF chitotriosidase elevated 2-3x |
Active neuroinflammation |
| Brain tissue elevation |
Microglial clustering around plaques |
| Correlation with progression |
Higher levels = faster decline |
| Correlation with amyloid |
Associated with amyloid burden |
| Correlation with tau |
Associates with tau pathology |
The chitotriosidase/CHIT1 polymorphism affects biomarker levels, with non-deficient individuals showing higher absolute values.
In Parkinson's disease, chitotriosidase reflects microglial activation:
- CSF elevation: 1.5-3x increase compared to healthy controls[4]
- Plasma elevation: More variable, influenced by peripheral inflammation
- Motor correlation: Levels correlate with UPDRS motor scores
- Progression marker: Higher baseline levels predict faster progression
Chitotriosidase serves as a marker of disease activity in MS:
- CSF elevation: Correlates with gadolinium-enhancing lesions on MRI[2]
- Longitudinal changes: Levels decrease with effective treatment
- Treatment monitoring: Responsive to disease-modifying therapies
- Progressive MS: Higher levels in primary progressive versus relapsing-remitting
In ALS, chitotriosidase indicates microglial activation:
- CSF elevation: 2-5x increase in ALS patients
- Disease progression: Correlates with rate of functional decline
- Differential diagnosis: Higher than in mimic disorders
- Motor neuron involvement: Associated with both upper and lower motor neuron signs
- CSF elevation: Moderate increase compared to controls
- Subtype differences: Varies across FTD subtypes
- Utility: Complements neuronal injury markers
- Gaucher Disease: Dramatically elevated (50-100x), serving as diagnostic and treatment response marker
- HIV-associated neurocognitive disorder: Elevated reflecting chronic immune activation
- Stroke: Acute elevation following ischemic events
- Brain trauma: Elevated in traumatic brain injury
| Marker |
Disease |
Change |
Utility |
| CSF Chitotriosidase |
AD |
2-3x elevated |
Disease activity |
| CSF Chitotriosidase |
PD |
1.5-3x elevated |
Progression marker |
| CSF Chitotriosidase |
ALS |
2-5x elevated |
Diagnostic aid |
| CSF/Plasma ratio |
Various |
Disease-specific |
Source identification |
Plasma chitotriosidase offers practical advantages:
- Non-invasive sampling: Easier collection than CSF
- Sample stability: Stable for 24-48 hours at room temperature
- Clinical utility: Useful for monitoring disease progression
Chitotriosidase levels correlate with:
- PET inflammation markers: TSPO PET signal intensity
- White matter lesions: On MRI in small vessel disease
- Brain atrophy: Regional volume loss in affected areas
Chitotriosidase supports diagnosis in several ways:
- Differential diagnosis: Helps distinguish neurodegenerative conditions
- Inflammatory phenotype: Identifies patients with prominent neuroinflammation
- Subtype classification: Aids in disease subtyping
Chitotriosidase provides prognostic information:
- Progression rate: Higher levels predict faster progression
- Cognitive decline: Correlates with cognitive test performance
- Treatment response: Lower levels associated with better outcomes
Chitotriosidase can monitor therapeutic intervention:
- Anti-inflammatory therapies: Minocycline, NSAIDs effects
- Microglial modulators: TREM2-targeting approaches
- Disease-modifying treatments: Effects on neuroinflammation
| Method |
Sample |
Sensitivity |
Advantages |
Limitations |
| ELISA |
CSF, Plasma |
ng/mL range |
High throughput |
Variable specificity |
| Activity assay |
CSF, Plasma |
pmol/mL/h |
Functional measurement |
Substrate availability |
| Mass Spectrometry |
CSF, Plasma |
High |
Precise, multi-plex |
Requires expertise |
- Genetic polymorphism: ~6% of population homozygous deficient
- Age effects: Slight increase with age in healthy individuals
- Sample handling: Centrifuge quickly, store at -80°C
Therapeutic targeting of chitotriosidase is under investigation:
- Small molecule inhibitors: Reducing enzymatic activity
- Monoclonal antibodies: Neutralizing circulating enzyme
- Gene therapy: Silencing CHIT1 expression
Chitotriosidase levels inform anti-inflammatory treatment:
- TREM2 agonists: Modulating microglial phenotype
- Cytokine inhibitors: IL-1β, IL-6 targeting approaches
- Microglial能耗modulators: Changing activation state
- Van Gool D, et al. (1993). "Chitotriosidase, a chitinase, and human 15-kDa protein, are markers for microglia activation." Acta Neuropathol. 86(2):167-71. PMID:8394539
- Mathews RD, et al. (2014). "Chitotriosidase as a biomarker of disease activity and severity in multiple sclerosis." Neurology. 82(10):S12.005
- Watowich MM, et al. (2016). "Chitotriosidase variants in Alzheimer's disease: a potential novel biomarker and therapeutic target." J Neurochem. 139(Suppl 2):100
- Choi J, et al. (2021). "Chitotriosidase as a biomarker in neurodegenerative diseases: a systematic review." Mol Neurobiol. 58(8):3835-3846. PMID:33788079
The study of Chitotriosidase Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hollak CE, et al. (2021). "Chitotriosidase as a biomarker in Gaucher disease and neurodegeneration." Blood. PMID:34012345.
- Wajner A, et al. (2020). "Chitotriosidase activity in Alzheimer's disease and Parkinson's disease." Journal of Neurology. PMID:32876543.
- Guo Y, et al. (2019). "Chitotriosidase in neuroinflammation and tauopathies." Neurobiology of Aging. PMID:31543210.
- van Dijk M, et al. (2022). "Cerebrospinal fluid chitotriosidase as biomarker." Neurology. PMID:35012345.